RGD-Binding Integrins in Head and Neck Cancers.
RGD-Binding Integrins in Head and Neck Cancers.
复制标题
DOI：
10.3390/cancers9060056
复制
发表时间：
2017-05-26
期刊：
影响因子：
5.2
通讯作者：
Sheldrake HM
中科院分区：
文献类型：
--
作者：
Ahmedah HT;Patterson LH;Shnyder SD;Sheldrake HM
整合素表达和功能的改变促进肿瘤生长、侵袭、转移和新生血管生成。头颈癌是高度血管性肿瘤，有转移倾向。它们表达多种整合素受体。αv和β1亚基的表达已被广泛研究，并与肿瘤的进展和转移有关。单个受体αvβ3和αvβ5已被证明是诊断和治疗药物的热门靶点，但研究较少的受体，如αvβ6、αvβ8和β1亚家族成员，也显示出希望。本文综述了整合素在头颈部鳞状细胞癌（HNSCC）中的表达和功能，特别关注精氨酸-甘氨酸-天门氨酸（RGD）结合整合素，以突出整合素作为个体化肿瘤特异性识别和治疗靶点的潜力。
Alterations in integrin expression and function promote tumour growth, invasion, metastasis and neoangiogenesis. Head and neck cancers are highly vascular tumours with a tendency to metastasise. They express a wide range of integrin receptors. Expression of the αv and β1 subunits has been explored relatively extensively and linked to tumour progression and metastasis. Individual receptors αvβ3 and αvβ5 have proved popular targets for diagnostic and therapeutic agents but lesser studied receptors, such as αvβ6, αvβ8, and β1 subfamily members, also show promise. This review presents the current knowledge of integrin expression and function in squamous cell carcinoma of the head and neck (HNSCC), with a particular focus on the arginine-glycine-aspartate (RGD)-binding integrins, in order to highlight the potential of integrins as targets for personalised tumour-specific identification and therapy.